FCF hit unprecedented -NZ$100.4m as capex doubled and debtors surged

This matters because the deterioration translated directly into a balance-sheet shift: net debt swung from a NZ$15.8m net cash position to NZ$89.0m of net debt, with gross borrowings rising 241.2% to NZ$147.5m.

Two drivers explain the swing. Operating working capital absorbed NZ$123.7m of cash – the upper edge of the supplied historical range, well above the NZ$51.4m average build – and capex doubled (+103.6%) to NZ$100.0m, lifting capex intensity to 7.7% of revenue from 3.6%. Operating cash flow consequently fell from NZ$55.4m to -NZ$0.5m.

On the income statement, revenue fell 4.4% to NZ$1.3b (below the normal range of -3.3% to 14.5%), but operating profit rose 20.9% to NZ$20.4m. PBT growth of -134.1% and NPAT growth of -161.6% sit below the operating line.

Operating profit improved 20.9%, yet OCF fell by NZ$55.8m and pre-lease FCF was negative by NZ$100.4m. The reported earnings recovery did not generate cash this year, which means investors have to look through the operating-profit line to working capital and capex to understand the result.

Trade debtors jumped 493% to NZ$138.8m, lifting receivable days from 6.3 to 38.8. Debtor days are still within Annolyse's historical range (mean 38.0 days, range 6.3–51.3), so this looks like a reversion from an unusually low FY21 base rather than a deterioration in collection quality. Even so, the NZ$115.4m absolute build is the single largest contributor to the working-capital absorption and most of the cash gap.

Leverage moved from net cash to net debt in one year. Gross borrowings rose by NZ$104.3m while cash was largely unchanged, taking net debt to NZ$89.0m. Total equity rose only NZ$6.6m, so the balance-sheet expansion was funded by debt, not retained earnings. This reduces financial flexibility heading into the next capex cycle.

HY22 NPAT was +NZ$2.9m, implying an H2 NPAT of -NZ$8.4m, so the second half is where the deterioration concentrated. H2 revenue at NZ$659.5m was roughly in line with H1, meaning the H2 weakness sat in margin, financing costs, and tax rather than in volume.

What the release does not support is a clean read-across to FY23: capex intensity at 7.7% is more than double the prior year, and management's investment trajectory and working-capital normalisation profile are not quantified here.

Below operating profit, PBT swung NZ$13.1m into loss and NPAT fell NZ$14.3m, with the PBT-to-NPAT gap widened by an effective tax rate of 74.2% (above Annolyse's historical range of -44.8% to 38.3%, and against a prior 38.3%). On the small PBT base, the tax line is a meaningful distortion, but PBT growth of -134.1% is itself the cleaner read and confirms a real below-operating-profit deterioration.

Earnings quality is materially weaker than the operating-profit line suggests. FCF-to-NPAT of 1,835.9% is mechanical (both numerator and denominator are negative and the cash outflow dwarfs the loss), and underlines that the loss was funded almost entirely by borrowing rather than offset by cash generation. The Apples segment – 59.4% of revenue – saw revenue fall NZ$76.8m and segment result drop from NZ$40.6m to NZ$27.8m, so the dominant business absorbed most of the operating pressure even though group operating profit ticked up.

This briefing cannot assess the underlying weather, pricing, and yield drivers behind the Apples segment decline, nor the company's collection experience on the enlarged trade-receivables book, because neither is quantified in the supplied materials.